Nebesio Todd D, Eugster Erica A
Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, 702 Barnhill Drive, Room 5960, Indianapolis, IN 46202, USA.
Int J Pediatr Endocrinol. 2010;2010:298937. doi: 10.1155/2010/298937. Epub 2010 Feb 1.
The treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is complex. In addition to disease control, important therapeutic goals are the maintenance of normal growth and the acquisition of normal reproductive function. Here, data regarding final adult height (FH) in patients with CAH will be reviewed. Additional difficulties associated with CAH, including risks of obesity and hypertension, will be discussed. Information about fertility and reproductive outcomes in men and women with CAH will also be summarized. Although the treatment of each child with CAH needs to be individualized, close medical followup and laboratory monitoring along with good compliance can often result in positive clinical outcomes.
由21-羟化酶缺乏引起的先天性肾上腺皮质增生症(CAH)的治疗较为复杂。除了疾病控制外,重要的治疗目标是维持正常生长以及获得正常生殖功能。在此,将对CAH患者的最终成人身高(FH)相关数据进行综述。还将讨论与CAH相关的其他困难,包括肥胖和高血压风险。也将总结CAH男性和女性的生育能力及生殖结局信息。尽管对每个CAH患儿的治疗都需要个体化,但密切的医学随访、实验室监测以及良好的依从性通常可带来积极的临床结果。